Bispecific Antibody-Drug Conjugate for PDGFR-β Internalization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDGFR-β therapeutic agents are inefficient in internalizing PDGFR-β, limiting the delivery of antibody-drug conjugates into cells expressing this receptor, which is crucial for treating neovascular diseases associated with excessive angiogenesis.
Innovation Solution
Development of an antibody or its antigen-binding fragment that specifically recognizes PDGF receptor-β, combined with a drug conjugate, to efficiently deliver chemotherapeutic agents to cells expressing PDGFR-β, utilizing a bispecific antibody approach to enhance internalization and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current PDGFR-β therapeutic agents are used, then treatment is provided, but internalization of PDGFR-β is inefficient, limiting drug delivery into cells
Solution Approach 1:
The patent employs a bispecific antibody construct that combines two antibody specificities: one targeting PDGFR-β for internalization and another targeting a different antigen to enhance cellular uptake. This composite antibody structure enables simultaneous engagement of multiple receptors, thereby improving both internalization efficiency and drug delivery productivity to PDGFR-β expressing cells
2Reliability
If chemotherapeutic agents are delivered to PDGFR-β expressing cells, then cytotoxicity is achieved, but toxicity to normal cells may occur
Solution Approach 1:
The bispecific antibody construct is designed to concentrate chemotherapeutic agents specifically at PDGFR-β expressing pathological sites through targeted binding. The localized delivery mechanism ensures high drug concentration at the disease site while maintaining low systemic levels, thereby achieving effective cytotoxicity at the target while minimizing toxicity to normal cells
3Measurement precision
If antibody-drug conjugate is designed for PDGFR-β targeting, then specific delivery is achieved, but internalization capability is insufficient
Solution Approach 1:
The bispecific antibody construct performs multiple functions simultaneously: it maintains high specificity for PDGFR-β targeting through one binding arm while the other arm engages additional cellular uptake mechanisms or receptors. This multi-functional design overcomes the limitation of conventional single-specificity antibodies that achieve targeting but fail to efficiently internalize, thereby resolving the contradiction between specificity and internalization capability
Data Source
AI summary
The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.